Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Non-alcoholic Fatty Liver Disease | 17 | 2024 | 405 | 5.490 |
Why?
|
| Liver Cirrhosis | 11 | 2024 | 877 | 1.570 |
Why?
|
| Elasticity Imaging Techniques | 5 | 2024 | 131 | 1.260 |
Why?
|
| Fatty Liver | 2 | 2023 | 191 | 0.950 |
Why?
|
| Hepatitis C, Chronic | 2 | 2019 | 347 | 0.880 |
Why?
|
| Liver Diseases | 3 | 2023 | 375 | 0.840 |
Why?
|
| Liver | 5 | 2021 | 1758 | 0.830 |
Why?
|
| Stomach Neoplasms | 2 | 2018 | 550 | 0.740 |
Why?
|
| Portal System | 1 | 2021 | 34 | 0.720 |
Why?
|
| Collateral Circulation | 1 | 2021 | 42 | 0.710 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2021 | 34 | 0.690 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 27 | 0.680 |
Why?
|
| Patient Safety | 1 | 2024 | 400 | 0.650 |
Why?
|
| Duty to Warn | 1 | 2019 | 2 | 0.630 |
Why?
|
| Professional Impairment | 1 | 2019 | 3 | 0.630 |
Why?
|
| Alcoholic Intoxication | 1 | 2019 | 11 | 0.620 |
Why?
|
| Confidentiality | 1 | 2019 | 103 | 0.580 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 2018 | 17 | 0.580 |
Why?
|
| Feeding Behavior | 1 | 2023 | 700 | 0.570 |
Why?
|
| Community Health Services | 1 | 2018 | 90 | 0.550 |
Why?
|
| Global Health | 2 | 2023 | 574 | 0.550 |
Why?
|
| Electric Impedance | 1 | 2017 | 65 | 0.540 |
Why?
|
| Anthropometry | 1 | 2017 | 198 | 0.520 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 150 | 0.520 |
Why?
|
| Alcoholism | 1 | 2019 | 233 | 0.520 |
Why?
|
| Mouth Neoplasms | 1 | 2017 | 85 | 0.510 |
Why?
|
| Patient Compliance | 1 | 2019 | 471 | 0.510 |
Why?
|
| Acculturation | 1 | 2016 | 68 | 0.510 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2016 | 81 | 0.500 |
Why?
|
| Cross-Sectional Studies | 8 | 2023 | 3456 | 0.500 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 111 | 0.500 |
Why?
|
| Arteriolosclerosis | 1 | 2015 | 2 | 0.490 |
Why?
|
| Spleen | 1 | 2016 | 281 | 0.490 |
Why?
|
| Severity of Illness Index | 1 | 2023 | 2933 | 0.480 |
Why?
|
| Mexican Americans | 1 | 2016 | 202 | 0.470 |
Why?
|
| Humans | 35 | 2024 | 126285 | 0.470 |
Why?
|
| Diabetic Angiopathies | 1 | 2015 | 67 | 0.470 |
Why?
|
| Middle Aged | 15 | 2024 | 27028 | 0.460 |
Why?
|
| Carcinoma | 1 | 2017 | 290 | 0.450 |
Why?
|
| Adult | 14 | 2024 | 29791 | 0.450 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 199 | 0.450 |
Why?
|
| Adipose Tissue | 1 | 2017 | 470 | 0.440 |
Why?
|
| Internship and Residency | 1 | 2024 | 1189 | 0.430 |
Why?
|
| Risk Factors | 10 | 2024 | 10372 | 0.430 |
Why?
|
| Mass Screening | 1 | 2019 | 785 | 0.430 |
Why?
|
| Prevalence | 6 | 2022 | 2483 | 0.420 |
Why?
|
| Exercise | 4 | 2023 | 828 | 0.420 |
Why?
|
| Obesity | 5 | 2024 | 2276 | 0.410 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 440 | 0.400 |
Why?
|
| Prebiotics | 1 | 2012 | 24 | 0.400 |
Why?
|
| Metagenome | 1 | 2012 | 149 | 0.370 |
Why?
|
| Male | 17 | 2024 | 62009 | 0.360 |
Why?
|
| Nutrition Surveys | 5 | 2022 | 298 | 0.360 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 698 | 0.350 |
Why?
|
| Female | 18 | 2024 | 67310 | 0.350 |
Why?
|
| Life Style | 3 | 2022 | 423 | 0.340 |
Why?
|
| Probiotics | 1 | 2012 | 220 | 0.330 |
Why?
|
| Alcohol Drinking | 2 | 2023 | 347 | 0.310 |
Why?
|
| Weight Loss | 2 | 2023 | 491 | 0.300 |
Why?
|
| Intestines | 1 | 2012 | 580 | 0.300 |
Why?
|
| Hypertension | 2 | 2021 | 1296 | 0.290 |
Why?
|
| Helicobacter pylori | 1 | 2017 | 1325 | 0.280 |
Why?
|
| Helicobacter Infections | 1 | 2017 | 1268 | 0.280 |
Why?
|
| United States | 7 | 2022 | 10988 | 0.280 |
Why?
|
| Biomarkers | 4 | 2021 | 3153 | 0.280 |
Why?
|
| Diet | 3 | 2023 | 1150 | 0.270 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2015 | 819 | 0.270 |
Why?
|
| Aspartate Aminotransferases | 2 | 2016 | 85 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2021 | 1282 | 0.260 |
Why?
|
| Alanine Transaminase | 2 | 2016 | 158 | 0.260 |
Why?
|
| Biopsy | 2 | 2020 | 1257 | 0.250 |
Why?
|
| Prospective Studies | 3 | 2022 | 6175 | 0.250 |
Why?
|
| Fibrosis | 3 | 2022 | 447 | 0.230 |
Why?
|
| Fast Foods | 1 | 2023 | 35 | 0.210 |
Why?
|
| Odds Ratio | 2 | 2016 | 1266 | 0.210 |
Why?
|
| Aged | 7 | 2024 | 19960 | 0.200 |
Why?
|
| Physicians, Primary Care | 1 | 2024 | 94 | 0.200 |
Why?
|
| Young Adult | 4 | 2018 | 9165 | 0.200 |
Why?
|
| Safety-net Providers | 2 | 2020 | 52 | 0.200 |
Why?
|
| Cluster Analysis | 1 | 2023 | 408 | 0.190 |
Why?
|
| Disease Management | 2 | 2018 | 529 | 0.190 |
Why?
|
| Hypertension, Portal | 2 | 2021 | 79 | 0.190 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 2900 | 0.190 |
Why?
|
| Public Health | 1 | 2023 | 269 | 0.180 |
Why?
|
| Proof of Concept Study | 1 | 2021 | 30 | 0.180 |
Why?
|
| Actigraphy | 1 | 2021 | 46 | 0.180 |
Why?
|
| Primary Health Care | 2 | 2024 | 772 | 0.170 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 3715 | 0.170 |
Why?
|
| Incidence | 2 | 2018 | 3166 | 0.170 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 525 | 0.160 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 274 | 0.160 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2019 | 40 | 0.150 |
Why?
|
| Health Behavior | 1 | 2022 | 387 | 0.150 |
Why?
|
| Linear Models | 1 | 2021 | 694 | 0.150 |
Why?
|
| Rooming-in Care | 1 | 2018 | 1 | 0.150 |
Why?
|
| Safety | 1 | 2019 | 222 | 0.150 |
Why?
|
| Hepatic Encephalopathy | 1 | 2019 | 83 | 0.140 |
Why?
|
| Urban Health | 1 | 2018 | 78 | 0.140 |
Why?
|
| Risk | 1 | 2020 | 769 | 0.140 |
Why?
|
| Emigration and Immigration | 1 | 2018 | 81 | 0.140 |
Why?
|
| Communicable Diseases | 1 | 2020 | 161 | 0.140 |
Why?
|
| End Stage Liver Disease | 1 | 2020 | 194 | 0.140 |
Why?
|
| Bile Ducts, Extrahepatic | 1 | 2017 | 14 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 171 | 0.140 |
Why?
|
| Latin America | 1 | 2017 | 93 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2024 | 728 | 0.140 |
Why?
|
| Asia | 1 | 2017 | 112 | 0.140 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6645 | 0.140 |
Why?
|
| Age Distribution | 1 | 2018 | 422 | 0.130 |
Why?
|
| Cooperative Behavior | 1 | 2018 | 221 | 0.130 |
Why?
|
| Work Schedule Tolerance | 1 | 2016 | 40 | 0.130 |
Why?
|
| Food Supply | 1 | 2017 | 101 | 0.130 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2017 | 99 | 0.130 |
Why?
|
| Retrospective Studies | 5 | 2022 | 16514 | 0.130 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 144 | 0.130 |
Why?
|
| Self Report | 1 | 2019 | 513 | 0.120 |
Why?
|
| Observer Variation | 1 | 2016 | 299 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 443 | 0.120 |
Why?
|
| Dyslipidemias | 1 | 2018 | 236 | 0.120 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2014 | 8 | 0.110 |
Why?
|
| Length of Stay | 1 | 2020 | 1325 | 0.110 |
Why?
|
| Hydrothorax | 1 | 2014 | 11 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2019 | 768 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 949 | 0.110 |
Why?
|
| Disease Progression | 1 | 2019 | 2103 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1436 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2024 | 3459 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 1334 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2018 | 653 | 0.100 |
Why?
|
| Logistic Models | 1 | 2016 | 1811 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2016 | 943 | 0.090 |
Why?
|
| Inflammation | 1 | 2019 | 1462 | 0.090 |
Why?
|
| Registries | 1 | 2018 | 1453 | 0.090 |
Why?
|
| Diarrhea | 1 | 2012 | 316 | 0.090 |
Why?
|
| Hospitalization | 1 | 2019 | 1800 | 0.090 |
Why?
|
| Age Factors | 1 | 2016 | 2834 | 0.080 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2012 | 205 | 0.080 |
Why?
|
| Texas | 1 | 2018 | 3586 | 0.080 |
Why?
|
| Quality of Life | 1 | 2019 | 1954 | 0.080 |
Why?
|
| Clostridium Infections | 1 | 2012 | 246 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2014 | 442 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 1972 | 0.070 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2012 | 306 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3341 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1111 | 0.070 |
Why?
|
| Prognosis | 1 | 2017 | 4731 | 0.070 |
Why?
|
| Time Factors | 1 | 2018 | 6334 | 0.070 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8302 | 0.060 |
Why?
|
| Physical Fitness | 1 | 2021 | 90 | 0.040 |
Why?
|
| Menopause | 1 | 2021 | 75 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2024 | 557 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2021 | 144 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2020 | 97 | 0.040 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2020 | 133 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 2194 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2024 | 1582 | 0.040 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 346 | 0.040 |
Why?
|
| Adolescent | 1 | 2015 | 19531 | 0.030 |
Why?
|
| Cross Infection | 1 | 2020 | 316 | 0.030 |
Why?
|
| Hospitals | 1 | 2019 | 397 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2019 | 393 | 0.030 |
Why?
|
| Child | 1 | 2015 | 24740 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1034 | 0.030 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2014 | 18 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1542 | 0.030 |
Why?
|
| Diuretics | 1 | 2014 | 167 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2020 | 4873 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2014 | 1204 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 2405 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2014 | 1077 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2020 | 12379 | 0.010 |
Why?
|